Methods for evaluating novel biomarkers - a new paradigm.
作者信息
Cook N R
机构信息
Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
出版信息
Int J Clin Pract. 2010 Dec;64(13):1723-7. doi: 10.1111/j.1742-1241.2010.02469.x.
Abstract
摘要
相似文献
1
Methods for evaluating novel biomarkers - a new paradigm.评估新型生物标志物的方法——一种新范式。
Int J Clin Pract. 2010 Dec;64(13):1723-7. doi: 10.1111/j.1742-1241.2010.02469.x.
2
Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians.心血管疾病风险预测模型在亚洲印度人群中的应用以及新型生物标志物与风险分层的相关性。
Vasc Health Risk Manag. 2008;4(1):199-211. doi: 10.2147/vhrm.2008.04.01.199.
3
Framework for evaluating novel risk markers.评估新型风险标志物的框架。
Ann Intern Med. 2012 Mar 20;156(6):468-9. doi: 10.7326/0003-4819-156-6-201203200-00013.
4
TIMI risk score accurately risk stratifies patients with undifferentiated chest pain presenting to an emergency department.TIMI风险评分能准确地对因不明原因胸痛就诊于急诊科的患者进行风险分层。
Heart. 2006 Sep;92(9):1333-4. doi: 10.1136/hrt.2005.080226.
5
Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers.开发肾损伤风险预测模型并评估新型生物标志物的增加值。
Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1488-96. doi: 10.2215/CJN.10351013. Epub 2014 May 22.
6
Multimarker approach to risk stratification among patients with advanced chronic heart failure.晚期慢性心力衰竭患者风险分层的多标志物方法
Clin Cardiol. 2007 Aug;30(8):397-402. doi: 10.1002/clc.20171.
7
Evaluating the impact of growth differentiation factor 15 on the risk of psoriasis.
Int J Rheum Dis. 2024 Aug;27(8):e15316. doi: 10.1111/1756-185X.15316.
8
Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle?血浆生物标志物预测心源性猝死：风险分层难题的又一环节？
Circ Arrhythm Electrophysiol. 2012 Feb;5(1):237-43. doi: 10.1161/CIRCEP.111.968057.
9
Paradigm shift from myocardium-derived to plaque-derived biomarkers for very early diagnosis of acute myocardial infarction.从心肌源性生物标志物到斑块源性生物标志物的范式转变用于急性心肌梗死的极早期诊断。
Circ J. 2011;75(6):1322-3. doi: 10.1253/circj.cj-11-0382. Epub 2011 Apr 29.
10
Comparing SF-36® scores versus biomarkers to predict mortality in primary cardiac prevention patients.比较 SF-36® 评分与生物标志物预测初级心脏预防患者的死亡率。
Eur J Intern Med. 2017 Dec;46:47-55. doi: 10.1016/j.ejim.2017.05.026. Epub 2017 Jul 29.
引用本文的文献
1
Improving cardiovascular risk prediction through machine learning modelling of irregularly repeated electronic health records.通过对不规则重复的电子健康记录进行机器学习建模来改善心血管风险预测。
Eur Heart J Digit Health. 2023 Oct 17;5(1):30-40. doi: 10.1093/ehjdh/ztad058. eCollection 2024 Jan.
2
Current understanding of the human microbiome in glioma.当前对胶质瘤中人类微生物组的认识。
Front Oncol. 2022 Aug 8;12:781741. doi: 10.3389/fonc.2022.781741. eCollection 2022.
3
Predicting Early Disease Recurrence of Pancreatic Cancer following Surgery: Determining the Role of NUDT15 as a Prognostic Biomarker.预测胰腺癌手术后早期复发：NUDT15 作为预后生物标志物的作用。
Curr Oncol. 2022 Apr 6;29(4):2516-2529. doi: 10.3390/curroncol29040206.
4
Current applications of capillary electrophoresis-mass spectrometry for the analysis of biologically important analytes in urine (2017 to mid-2021): A review.毛细管电泳-质谱法在尿液中生物重要分析物分析中的当前应用（2017 年至 2021 年年中）：综述。
J Sep Sci. 2022 Jan;45(1):305-324. doi: 10.1002/jssc.202100621. Epub 2021 Oct 7.
5
The Oral Microbiome and Cancer.口腔微生物群与癌症
Front Immunol. 2020 Oct 23;11:591088. doi: 10.3389/fimmu.2020.591088. eCollection 2020.
6
Waist circumference does not improve established cardiovascular disease risk prediction modeling.腰围并不能改善已确立的心血管疾病风险预测模型。
PLoS One. 2020 Oct 2;15(10):e0240214. doi: 10.1371/journal.pone.0240214. eCollection 2020.
7
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity.腰围作为临床实践中的生命体征：IAS 和 ICCR 内脏肥胖工作组的共识声明。
Nat Rev Endocrinol. 2020 Mar;16(3):177-189. doi: 10.1038/s41574-019-0310-7. Epub 2020 Feb 4.
8
Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT).利用人群健康调查开发和验证心血管疾病风险预测模型：心血管疾病人群风险工具（CVDPoRT）。
CMAJ. 2018 Jul 23;190(29):E871-E882. doi: 10.1503/cmaj.170914.
9
Evaluation of the use of the fourth version FloTrac system in cardiac output measurement before and after cardiopulmonary bypass.体外循环前后使用第四版FloTrac系统测量心输出量的评估。
J Clin Monit Comput. 2018 Oct;32(5):807-815. doi: 10.1007/s10877-017-0071-6. Epub 2017 Oct 16.
10
Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke.可溶性ST2可预测急性中风后的预后及出血性转化。
Ann Clin Transl Neurol. 2017 Jul 5;4(8):553-563. doi: 10.1002/acn3.435. eCollection 2017 Aug.
本文引用的文献
1
Reclassification calculations for persons with incomplete follow-up.对随访不完整者的重新分类计算。
Ann Intern Med. 2010 Feb 2;152(3):195-6; author reply 196-7. doi: 10.7326/0003-4819-152-3-201002020-00019.
2
C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study.弗雷明汉心脏研究中C反应蛋白与心血管风险重新分类
Circ Cardiovasc Qual Outcomes. 2008 Nov;1(2):92-7. doi: 10.1161/CIRCOUTCOMES.108.831198. Epub 2008 Nov 9.
3
Biomarkers for prediction of cardiovascular events.用于预测心血管事件的生物标志物。
JAMA. 2009 Nov 18;302(19):2089; author reply 2090. doi: 10.1001/jama.2009.1636.
4
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.用于预测社区中心血管事件发生的新型和传统生物标志物。
JAMA. 2009 Jul 1;302(1):49-57. doi: 10.1001/jama.2009.943.
5
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures.心血管风险个体预测因素效应测量的进展：重新分类测量的作用。
Ann Intern Med. 2009 Jun 2;150(11):795-802. doi: 10.7326/0003-4819-150-11-200906020-00007.
6
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.C反应蛋白和家族病史可改善总体心血管风险预测：男性的雷诺兹风险评分
Circulation. 2008 Nov 25;118(22):2243-51, 4p following 2251. doi: 10.1161/CIRCULATIONAHA.108.814251. Epub 2008 Nov 9.
7
Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).对M. J. 彭西纳等人发表于《医学统计学》（DOI: 10.1002/sim.2929）的《评估新标志物的附加预测能力：从ROC曲线下面积到重新分类及其他》的评论
Stat Med. 2008 Jan 30;27(2):173-81. doi: 10.1002/sim.2991.
8
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.评估新标志物的附加预测能力：从ROC曲线下面积到重新分类及其他。
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12. doi: 10.1002/sim.2929.
9
Use and misuse of the receiver operating characteristic curve in risk prediction.风险预测中受试者工作特征曲线的应用与误用
Circulation. 2007 Feb 20;115(7):928-35. doi: 10.1161/CIRCULATIONAHA.106.672402.
10
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.女性全球心血管风险评估改良算法的开发与验证：雷诺兹风险评分
JAMA. 2007 Feb 14;297(6):611-9. doi: 10.1001/jama.297.6.611.
Zotero 插件